WEBVTT	#Elemental Media Engine(TM) 2.17.1.0

00:00:00.734 --> 00:00:01.468
Denmark's Novo Nordisk
-Ablynx.

00:00:02.168 --> 00:00:04.838
We are launching our
once-weekly GLP-1,

00:00:04.938 --> 00:00:06.573
Ozempic in the US
market. We also have a

00:00:06.673 --> 00:00:08.041
big obesity business.

00:00:08.141 --> 00:00:10.343
We will continuously
roll out our innovative

00:00:10.443 --> 00:00:11.978
portfolio of GLP-1s.

00:00:12.078 --> 00:00:13.813
Here's a two-week chart
of the S & P.

00:00:13.913 --> 00:00:16.883
But 2500 would be an
important support

00:00:16.983 --> 00:00:17.217
And sales surge at Novo
Nordisk.

00:00:17.317 --> 00:00:18.218
level.

00:00:18.718 --> 00:00:20.720
The CEO says the firm
is seeing a gradual

00:00:20.820 --> 00:00:23.623
recovery in patients
initiating diabetes

00:00:23.723 --> 00:00:25.025
treatment. They also
have a recently

00:00:25.125 --> 00:00:27.394
approved drug for
weight loss with really

00:00:27.494 --> 00:00:28.495
extreme results.

00:00:28.595 --> 00:00:32.265
So how does Wegovy
help you lose weight?

00:00:32.365 --> 00:00:35.235
We have a very
efficacious product now

00:00:35.335 --> 00:00:37.704
on the market in the
US. Wegovy.

00:00:37.804 --> 00:00:38.905
Novo was the only
company with FDA

00:00:39.005 --> 00:00:40.573
approval to market
Wegovy.

00:00:40.673 --> 00:00:42.275
Other than the fact
that that chart's about

00:00:42.375 --> 00:00:43.910
the greatest chart
you've ever seen and

00:00:44.010 --> 00:00:45.712
that's all about one
drug mostly, David.

00:00:45.812 --> 00:00:46.379
It's a drug called
Wegovy.

00:00:47.080 --> 00:00:49.916
A new blockbuster
obesity drug Wegovy.

00:00:50.050 --> 00:00:51.384
Novo Nordisk.

00:00:51.484 --> 00:00:53.253
Ozempic and Wegovy.
Shares of Novo Nordisk

00:00:53.353 --> 00:00:54.621
are up sharply this
morning. That the

00:00:54.721 --> 00:00:56.990
weight loss drug
Wegovy. Novo Nordisk.

00:00:57.090 --> 00:00:59.125
Here's a headline
Dethroning LVMH as

00:00:59.225 --> 00:01:01.661
Europe's most valuable
company thanks to

00:01:01.795 --> 00:01:02.128
Wegovy.

00:01:09.903 --> 00:01:11.805
Well, here it is
Saturday morning.

00:01:11.905 --> 00:01:14.541
It's the day that I
give myself my Ozempic

00:01:14.641 --> 00:01:18.111
injection. This is my
box of Ozempic.

00:01:19.212 --> 00:01:21.214
This is 65 year old
Mary Tripp.

00:01:21.314 --> 00:01:23.083
She's struggled with
her weight since she

00:01:23.183 --> 00:01:24.617
was 11 years old.

00:01:24.751 --> 00:01:28.988
I did have times in my
life where, um, you

00:01:29.089 --> 00:01:32.492
know, it was hard for
me to get out and take

00:01:32.592 --> 00:01:35.361
a walk or get out and
do anything.

00:01:35.462 --> 00:01:39.099
I mean, it was, you
know, and at those

00:01:39.199 --> 00:01:41.968
times, yes. I mean, I
felt like a failure.

00:01:42.068 --> 00:01:44.704
While a gastric bypass
operation in 2005

00:01:44.804 --> 00:01:47.040
reversed her Type 2
diabetes, the weight

00:01:47.140 --> 00:01:49.876
wouldn't stay off
until summer 2022 when

00:01:49.976 --> 00:01:52.745
her doctor recommended
she try Ozempic.

00:01:53.947 --> 00:01:57.851
We tried different
diabetes drugs that,

00:01:57.951 --> 00:01:59.619
you know, that also
help you lose weight.

00:01:59.719 --> 00:02:02.055
But there was a
several of the older

00:02:02.155 --> 00:02:03.756
ones that I was
allergic to.

00:02:03.857 --> 00:02:07.560
So then it had been a
number of years and,

00:02:07.660 --> 00:02:09.496
and you know, I was
kind of saying to her

00:02:09.596 --> 00:02:10.930
like, is there
anything else we can

00:02:11.030 --> 00:02:16.436
do? And she said, Why
don't we try Ozempic

00:02:16.536 --> 00:02:18.171
and see how that goes.

00:02:18.271 --> 00:02:20.840
Her diabetes made her a
prime candidate for the

00:02:20.940 --> 00:02:24.344
drug. She's lost about
60 pounds since June

00:02:24.444 --> 00:02:26.913
2022. Results like
Mary's are part of why

00:02:27.013 --> 00:02:28.548
there's a global surge
in demand for

00:02:28.648 --> 00:02:31.184
Semaglutide sold under
the name Ozempic for

00:02:31.284 --> 00:02:33.753
patients with diabetes
and Wegovy for those

00:02:33.853 --> 00:02:34.787
seeking weight loss.

00:02:34.888 --> 00:02:36.823
In 2021, national
spending for

00:02:36.923 --> 00:02:40.627
Semaglutide totaled
$10.7 billion.

00:02:40.727 --> 00:02:43.163
Danish pharmaceutical
company Novo Nordisk

00:02:43.263 --> 00:02:44.964
developed it,
transforming an

00:02:45.064 --> 00:02:47.500
untapped industry and
likely the company's

00:02:47.600 --> 00:02:49.335
fortunes forever.

00:02:49.435 --> 00:02:51.104
This is going to be one
of the biggest, the

00:02:51.204 --> 00:02:53.173
highest demand drugs
in the history of

00:02:53.273 --> 00:02:54.174
pharmaceuticals.

00:02:54.274 --> 00:02:56.342
While diabetes drugs
have been effective for

00:02:56.442 --> 00:02:58.912
decades, drugs for
weight loss have not.

00:02:59.012 --> 00:03:01.080
And the potential
impact is huge.

00:03:01.181 --> 00:03:03.316
More than 1 billion
people suffer from

00:03:03.416 --> 00:03:04.784
obesity worldwide.

00:03:04.884 --> 00:03:07.754
It's been a crazy ride
and it's it's still

00:03:07.854 --> 00:03:09.556
ongoing. It's clear
that nobody had

00:03:09.656 --> 00:03:12.825
expected that it would
be taking off this

00:03:12.926 --> 00:03:13.159
In September 2023,
CNBC's Melissa Lee got

00:03:13.259 --> 00:03:16.596
quickly.

00:03:16.696 --> 00:03:18.998
an inside look at a
Novo Nordisk lab in

00:03:19.098 --> 00:03:22.068
Denmark. Novo Nordisk
didn't set out to

00:03:22.168 --> 00:03:24.170
create a weight loss
drug. It was an

00:03:24.270 --> 00:03:26.706
unintentional side
effect discovered while

00:03:26.806 --> 00:03:28.508
studying GLP-1s.

00:03:28.741 --> 00:03:31.411
We had no clue about
this molecule, will

00:03:31.511 --> 00:03:34.247
come out with higher
efficacy than our past

00:03:34.347 --> 00:03:35.748
versions of of these
molecules.

00:03:36.382 --> 00:03:38.284
Semaglutide is the
medical name for

00:03:38.384 --> 00:03:41.054
Ozempic and Wegovy and
falls under a class of

00:03:41.154 --> 00:03:42.422
drugs called GLP-1
agonists.

00:03:43.289 --> 00:03:45.725
GLP-1 drugs mimic
GLP-1 molecules in the

00:03:45.825 --> 00:03:48.094
body and regulate
blood sugar, stimulate

00:03:48.194 --> 00:03:51.130
insulin production and
suppress appetite.

00:03:51.264 --> 00:03:52.699
I guess that's what
I've been looking for

00:03:52.799 --> 00:03:55.268
is something that will
like tell my brain you

00:03:55.368 --> 00:03:57.737
really don't need this
and you really don't

00:03:57.837 --> 00:03:58.771
want it.

00:03:58.871 --> 00:04:00.573
We knew we had a type
two diabetes product,

00:04:00.673 --> 00:04:02.809
but we also talked
about if it actually

00:04:02.909 --> 00:04:05.945
works in obesity, do
we dare to go in and do

00:04:06.045 --> 00:04:06.980
that development?

00:04:07.080 --> 00:04:09.015
As it often plays out
in research, there's

00:04:09.115 --> 00:04:11.050
also some surprises on
the way.

00:04:11.150 --> 00:04:12.785
Semaglutide was
developed in the early

00:04:12.885 --> 00:04:16.222
2000s and released in
2012 as Ozempic a

00:04:16.322 --> 00:04:18.191
weekly injection for
those with Type 2

00:04:18.291 --> 00:04:22.895
diabetes. It passed
FDA approval in 2017.

00:04:22.996 --> 00:04:24.564
Wegovy was approved in
2021.

00:04:25.765 --> 00:04:27.700
Neither were an
immediate hit.

00:04:27.800 --> 00:04:29.435
Weight loss drugs
already in the market

00:04:29.535 --> 00:04:31.170
weren't as effective,
which made it

00:04:31.271 --> 00:04:32.672
challenging when
trying to promote to

00:04:32.772 --> 00:04:34.974
those disillusioned
with the diet industry.

00:04:35.341 --> 00:04:38.344
Many who live with
obesity have tried a

00:04:38.444 --> 00:04:40.313
lot of different
things and often

00:04:40.413 --> 00:04:42.715
failed. So actually,
just mobilizing

00:04:42.815 --> 00:04:46.419
patients to seek care
is is not easy.

00:04:46.519 --> 00:04:49.455
It was not a huge
success, so to say.

00:04:49.555 --> 00:04:51.991
Doctors say demand took
off when fear about

00:04:52.091 --> 00:04:53.993
death was spreading
during the Covid-19

00:04:54.093 --> 00:04:56.396
pandemic. According to
the Centers for Disease

00:04:56.496 --> 00:04:58.431
Control and
Prevention, obesity

00:04:58.531 --> 00:05:01.234
could triple the risk
of hospitalization.

00:05:01.334 --> 00:05:03.469
That was the moment
that everything

00:05:03.569 --> 00:05:06.239
shifted. I remember
having patients coming

00:05:06.339 --> 00:05:08.207
to me, patients with
obesity or struggling

00:05:08.308 --> 00:05:10.543
with weight,
specifically saying, I

00:05:10.677 --> 00:05:13.012
don't want to die from
Covid due to my weight.

00:05:13.112 --> 00:05:15.815
In 2020, more than a
million US patients

00:05:15.915 --> 00:05:18.718
were prescribed
Semaglutide. In 2021,

00:05:18.818 --> 00:05:21.554
that number jumped to
about 2 million.

00:05:21.654 --> 00:05:23.489
They didn't see it
coming. No one saw it

00:05:23.589 --> 00:05:27.627
come. Investors didn't
and analysts didn't.

00:05:27.794 --> 00:05:31.030
This one drug alone
could be worth 200 $300

00:05:31.130 --> 00:05:33.066
billion over time.

00:05:39.572 --> 00:05:43.276
I think we were maybe 6
to 10 people working on

00:05:43.376 --> 00:05:45.945
that project. 6 to 10
people in the lab like

00:05:46.045 --> 00:05:48.915
this? Yeah, we were in
different labs.

00:05:49.115 --> 00:05:50.917
Pow Bloch was one of
the scientists in the

00:05:51.017 --> 00:05:51.918
early phases of
Semaglutide's

00:05:52.685 --> 00:05:53.586
discovery.

00:05:53.686 --> 00:05:58.057
I made a Semaglutide
the first time in 2004,

00:05:58.157 --> 00:06:01.794
so it was a long
process before we hit

00:06:01.894 --> 00:06:02.762
the right one.

00:06:02.862 --> 00:06:05.298
But Novo Nordisk's
100-year history began

00:06:05.398 --> 00:06:07.900
with the desire to
cure diabetes, as one

00:06:08.000 --> 00:06:09.369
of the company's
founders had the

00:06:09.469 --> 00:06:12.438
disease. In 1922, a
group of scientists

00:06:12.538 --> 00:06:14.574
traveled to Canada to
bring back a new

00:06:14.674 --> 00:06:17.377
miracle drug insulin
to Scandinavia, leading

00:06:17.477 --> 00:06:18.411
to the founding of
Nordisk

00:06:18.911 --> 00:06:20.446
InsulinLaboratorium.

00:06:20.546 --> 00:06:23.449
Less than three months
later, they treated the

00:06:23.549 --> 00:06:25.318
first ten patients.

00:06:25.418 --> 00:06:28.254
And they didn't have
anything at all when

00:06:28.354 --> 00:06:31.424
they started. It was
made in a basement.

00:06:31.591 --> 00:06:33.326
A few years later, two
former Nordisk

00:06:33.426 --> 00:06:35.795
employees started
their own company, Novo

00:06:35.895 --> 00:06:38.631
Therapeutic. Novo
Nordisk competed as the

00:06:38.731 --> 00:06:40.666
world's leading
insulin producers until

00:06:40.767 --> 00:06:43.970
finally merging in
1989 to become Novo

00:06:44.070 --> 00:06:44.737
Nordisk.

00:06:44.837 --> 00:06:46.773
They saw this
competition on a

00:06:46.873 --> 00:06:49.208
transatlantic
perspective and

00:06:49.308 --> 00:06:52.111
globally, and there
were huge demands for

00:06:52.211 --> 00:06:54.547
investments in
development and

00:06:54.647 --> 00:06:55.548
research.

00:06:55.648 --> 00:06:58.084
In August 2023, the
company became Europe's

00:06:58.184 --> 00:07:00.453
most valuable company
by market cap, more

00:07:00.553 --> 00:07:02.455
valuable than its home
country. Denmark's

00:07:02.555 --> 00:07:05.725
total economy, its
second quarter earnings

00:07:05.825 --> 00:07:07.160
in 2023, followed
suit.

00:07:07.727 --> 00:07:10.563
The company reported a
46% increase in net

00:07:10.663 --> 00:07:13.332
profits and a 32%
increase in sales

00:07:13.433 --> 00:07:15.401
compared to the same
quarter the year prior.

00:07:15.501 --> 00:07:18.538
Sales of Ozempic and
Wegovy rose by 58% and

00:07:18.638 --> 00:07:22.175
363% respectively in
the first six months of

00:07:22.275 --> 00:07:24.744
2023. And in the same
period, the company

00:07:24.844 --> 00:07:29.182
recorded overall net
sales of $15.1 billion.

00:07:29.282 --> 00:07:30.817
To put that in
perspective, the year

00:07:30.917 --> 00:07:33.619
Novo Nordisk developed
Semaglutide in 2012,

00:07:33.719 --> 00:07:35.555
the company's full
year net sales were

00:07:35.655 --> 00:07:37.623
$13.5 billion.

00:07:37.723 --> 00:07:39.559
In the past five
years, the share price

00:07:39.659 --> 00:07:41.794
of Novo Nordisk has
more than quadrupled.

00:07:41.894 --> 00:07:45.364
The stock sold for
$89.99 as of October

00:07:45.465 --> 00:07:46.866
5th, 2023.

00:07:46.966 --> 00:07:50.002
We haven't seen any
performance even close

00:07:50.102 --> 00:07:50.970
to this.

00:07:51.070 --> 00:07:52.905
Just days prior to
second quarter earnings

00:07:53.005 --> 00:07:55.374
in 2023, it was
reported that a late

00:07:55.475 --> 00:07:57.610
stage clinical trial
showed Wegovy reduced

00:07:57.710 --> 00:07:59.345
the risk of
cardiovascular events

00:07:59.445 --> 00:08:02.782
like heart attacks or
strokes by 20% compared

00:08:02.882 --> 00:08:06.853
to a placebo. Shares
soared by 17% that day.

00:08:06.953 --> 00:08:09.255
The select trial
exceeded expectations

00:08:09.355 --> 00:08:10.857
and helped the company
showcase the drug's

00:08:10.957 --> 00:08:13.626
potential beyond its
image as a vanity drug.

00:08:13.726 --> 00:08:16.162
We all saw that, okay,
this is not just about

00:08:16.262 --> 00:08:17.163
weight.

00:08:17.263 --> 00:08:19.265
The select trial was
really, you know, one

00:08:19.365 --> 00:08:21.033
of the bigger moments,
I believe, in health

00:08:21.133 --> 00:08:23.736
care over the past few
years, aside from Covid

00:08:23.836 --> 00:08:27.507
vaccines. And if these
data stick over the

00:08:27.607 --> 00:08:30.476
long term, we can come
up with numbers that we

00:08:30.576 --> 00:08:33.212
just have not seen for
other therapeutics.

00:08:33.312 --> 00:08:35.248
The company raised its
full year profit and

00:08:35.348 --> 00:08:37.617
sales forecasts for a
second time.

00:08:38.017 --> 00:08:41.988
We felt comfortable all
along that dealing with

00:08:42.088 --> 00:08:44.824
obesity is actually
leading to a number of

00:08:44.924 --> 00:08:46.726
health benefits. So
far, we have developed

00:08:46.826 --> 00:08:48.728
it for Type 2 diabetes
and obesity.

00:08:48.828 --> 00:08:50.897
We are testing it out
also in Alzheimer's.

00:08:50.997 --> 00:08:53.165
One of the reasons why
it works in obesity is

00:08:53.266 --> 00:08:54.700
that it deals with
your craving.

00:08:54.800 --> 00:08:57.770
So you say addiction
for for food.

00:08:57.870 --> 00:08:59.438
There are some
speculations that close

00:08:59.539 --> 00:09:01.741
to that center in the
brain is also the

00:09:01.841 --> 00:09:02.642
control of other
addictions.

00:09:03.175 --> 00:09:05.144
While the company
continues to diversify

00:09:05.244 --> 00:09:08.581
its portfolio, at the
moment, it is all in on

00:09:08.681 --> 00:09:10.750
obesity care. Later in
August, the company

00:09:10.850 --> 00:09:12.852
acquired competitor
embark biotech for

00:09:12.952 --> 00:09:17.456
$16.3 million up front
and up to $498 million

00:09:17.557 --> 00:09:19.892
in milestone payments
and drug developer

00:09:19.992 --> 00:09:23.296
inverse Argo Pharma
for about $1 billion.

00:09:30.603 --> 00:09:33.306
More than 100 million
US adults are living

00:09:33.406 --> 00:09:36.542
with obesity. In its
2020 report, the Milken

00:09:36.642 --> 00:09:38.544
Institute found that
the economic and social

00:09:38.644 --> 00:09:41.280
impacts of the disease
in the US alone account

00:09:41.380 --> 00:09:43.082
for nearly $1.4
trillion.

00:09:44.250 --> 00:09:46.719
Its estimated annual
medical US costs were

00:09:46.819 --> 00:09:49.388
nearly $173 billion in
2019.

00:09:51.223 --> 00:09:53.559
Type 2 diabetes and
obesity go hand in

00:09:53.659 --> 00:09:55.461
hand. So by improving
one, we improve the

00:09:55.561 --> 00:09:57.964
other one, right? But
if we look at it in the

00:09:58.064 --> 00:10:01.500
obesity weight loss
side, we are preventing

00:10:01.601 --> 00:10:04.203
Type 2 diabetes by
treating obesity.

00:10:04.337 --> 00:10:07.306
Yet obesity is largely
an untapped market.

00:10:07.406 --> 00:10:09.675
Prior to GLP 1s,
previous weight loss

00:10:09.775 --> 00:10:11.377
drugs were either
ineffective or had

00:10:11.477 --> 00:10:13.245
dangerous side
effects, like the diet

00:10:13.346 --> 00:10:15.615
drug combo Fen-Phen in
the 90s that was linked

00:10:15.715 --> 00:10:18.351
to heart and lung
damage in clinical

00:10:18.451 --> 00:10:20.419
trials, Wegovy was
shown to reduce body

00:10:20.519 --> 00:10:23.322
weight in people with
a BMI of 27 or greater

00:10:23.422 --> 00:10:25.491
by around 15%.

00:10:25.591 --> 00:10:27.493
There's always been a
barrier to break

00:10:27.593 --> 00:10:30.296
through weight loss of
about 10%.

00:10:30.396 --> 00:10:32.231
That's always been the
view that once you

00:10:32.331 --> 00:10:34.700
break through 10%,
this becomes a very,

00:10:34.800 --> 00:10:35.735
very real market.

00:10:35.835 --> 00:10:40.339
And Novo achieved
that, frankly, with

00:10:40.439 --> 00:10:40.673
While Novo Nordisk is a
first mover in obesity

00:10:40.773 --> 00:10:43.075
Wegovy.

00:10:43.175 --> 00:10:44.944
care, the company
can't solve the

00:10:45.044 --> 00:10:47.813
epidemic alone. There
are 1 billion people

00:10:47.913 --> 00:10:49.448
suffering worldwide.

00:10:49.682 --> 00:10:53.452
To be able to support
all of the patients who

00:10:53.552 --> 00:10:56.022
are diagnosed or who
would be diagnosed as

00:10:56.122 --> 00:10:58.357
obese in the US
market, you'd have to

00:10:58.457 --> 00:11:01.293
be able to supply over
50 billion pens.

00:11:01.394 --> 00:11:04.163
That's a pretty
daunting task just to

00:11:04.263 --> 00:11:04.997
manufacture the
devices.

00:11:05.698 --> 00:11:08.868
In 2032, Novo Nordisk's
Semaglutide patent

00:11:08.968 --> 00:11:10.436
expires in the US.

00:11:10.536 --> 00:11:11.137
Many other
pharmaceutical

00:11:11.704 --> 00:11:14.140
companies are joining
the race by developing

00:11:14.240 --> 00:11:17.309
their own GLP-1 drugs
like Eli Lilly, which

00:11:17.410 --> 00:11:19.378
analysts say is Novo
Nordisk's biggest

00:11:19.478 --> 00:11:20.246
competitor.

00:11:20.346 --> 00:11:22.715
Amgen and Pfizer are
also working on

00:11:22.815 --> 00:11:23.849
products there.

00:11:23.949 --> 00:11:25.418
There's a number of
other companies,

00:11:25.518 --> 00:11:29.655
including Viking and
Structure on the small

00:11:29.755 --> 00:11:32.124
cap biotech side that
are vying for

00:11:32.224 --> 00:11:33.092
positioning here as
well.

00:11:33.659 --> 00:11:36.595
Eli Lilly's Tirzepatide
sold as Manjaro is more

00:11:36.696 --> 00:11:39.065
effective and boosts
higher weight loss

00:11:39.165 --> 00:11:41.333
results than
Semaglutide. Unlike

00:11:41.434 --> 00:11:44.303
Wegovy, Manjaro is not
yet FDA-approved for

00:11:44.403 --> 00:11:46.572
weight loss, but
expected to be in late

00:11:46.672 --> 00:11:48.974
2023 or early 2024.

00:11:49.075 --> 00:11:51.277
I like competition
because if there's no

00:11:51.377 --> 00:11:54.880
competition, there is
a risk that we do not

00:11:54.980 --> 00:11:57.383
stay innovative. So we
have been competing

00:11:57.483 --> 00:11:59.285
with Eli Lilly for 100
years.

00:12:05.157 --> 00:12:07.493
While growth has been
explosive, there are

00:12:07.593 --> 00:12:08.828
some concerns.

00:12:08.928 --> 00:12:11.397
For one, massive
demand for both Ozempic

00:12:11.497 --> 00:12:14.066
and Wegovy has caused
real supply shortages.

00:12:14.166 --> 00:12:15.868
The company is
expanding production

00:12:15.968 --> 00:12:18.604
capacity in its North
Carolina and Denmark

00:12:18.704 --> 00:12:19.638
facilities.

00:12:19.739 --> 00:12:22.007
If you look at just the
growth of go in the US,

00:12:22.108 --> 00:12:24.977
it's, you know, it's
more than doubling year

00:12:25.077 --> 00:12:27.079
over year. So more and
more capacity is coming

00:12:27.179 --> 00:12:27.980
in line.

00:12:28.080 --> 00:12:30.349
Off-label use is
another consideration.

00:12:30.449 --> 00:12:32.184
Everybody looks so
great. When I look

00:12:32.284 --> 00:12:34.186
around this room, I
can't help but wonder

00:12:34.286 --> 00:12:35.788
is Ozempic right for
me?

00:12:37.590 --> 00:12:40.226
As Jimmy Kimmel joked
at the 2023 Oscars,

00:12:40.326 --> 00:12:42.128
celebrities are
reportedly using these

00:12:42.228 --> 00:12:44.430
drugs to lose a few
extra pounds.

00:12:44.530 --> 00:12:46.766
They wouldn't be the
first. A recent study

00:12:46.866 --> 00:12:49.435
by data analytics firm
Trilliant Health found

00:12:49.535 --> 00:12:51.670
that only a little
more than half of US

00:12:51.771 --> 00:12:54.140
patients on GLP-1
drugs have a history of

00:12:54.240 --> 00:12:56.575
Type 2 diabetes or
received a prescription

00:12:56.675 --> 00:12:58.077
after a medical visit.

00:12:58.811 --> 00:13:01.247
It's a challenging
situation because it's

00:13:01.347 --> 00:13:03.816
a it's a new situation
for us.

00:13:03.916 --> 00:13:06.051
It's something we
cannot control.

00:13:06.152 --> 00:13:08.087
So we are really
doubling down in making

00:13:08.187 --> 00:13:11.490
sure that physicians
are educated around our

00:13:11.590 --> 00:13:12.491
products.

00:13:12.591 --> 00:13:14.593
But some experts don't
necessarily see off

00:13:14.693 --> 00:13:17.296
label use as an issue
and rather a challenge

00:13:17.396 --> 00:13:19.532
to solve for the
future. After treatment

00:13:19.632 --> 00:13:21.000
becomes available for
those who need it

00:13:21.100 --> 00:13:23.135
most, the next step is
likely reaching the

00:13:23.235 --> 00:13:25.304
average consumer. That
is, people who want to

00:13:25.404 --> 00:13:26.238
lose a little extra
weight.

00:13:26.639 --> 00:13:31.510
Consumer products don't
command the same profit

00:13:31.610 --> 00:13:33.412
margins that
pharmaceutical products

00:13:33.512 --> 00:13:37.082
do. But in terms of
being able to scale

00:13:37.183 --> 00:13:39.218
into a market, this
vast- The ability to

00:13:39.318 --> 00:13:42.588
kind of take this to
the consumer, assuming

00:13:42.688 --> 00:13:45.624
that we continue to
see good safety of this

00:13:45.724 --> 00:13:49.195
category over time,
would be potentially a

00:13:49.295 --> 00:13:51.931
next leg of the story,
not just for Novo

00:13:52.031 --> 00:13:54.300
Nordisk, but also for
the industry.

00:13:54.400 --> 00:13:57.937
If they can't innovate
successfully beyond

00:13:58.037 --> 00:14:00.439
Semaglutide, that's a
fundamental problem for

00:14:00.539 --> 00:14:02.274
the pharmaceutical
industry that they have

00:14:02.374 --> 00:14:03.142
to solve for.

00:14:03.242 --> 00:14:05.044
There are some
questions about side

00:14:05.144 --> 00:14:07.313
effects. Many users
have reported

00:14:07.413 --> 00:14:09.815
experiencing minor
symptoms like nausea.

00:14:09.915 --> 00:14:13.252
Others more serious,
like stomach paralysis,

00:14:13.352 --> 00:14:16.155
depression and
suicidal thoughts.

00:14:16.288 --> 00:14:19.024
On October 5th, 2023,
a study, the first of

00:14:19.124 --> 00:14:21.594
its kind, found an
increased risk of

00:14:21.694 --> 00:14:23.996
gastrointestinal
issues stemming from

00:14:24.096 --> 00:14:25.598
GLP -1 drugs.

00:14:25.798 --> 00:14:27.967
The Danish drugmaker,
along with Eli Lilly,

00:14:28.067 --> 00:14:30.135
was already facing a
lawsuit over what

00:14:30.236 --> 00:14:32.805
plaintiffs say is a
failure to disclose

00:14:32.905 --> 00:14:33.706
these types of health
issues.

00:14:34.874 --> 00:14:37.910
Any report of a safety
issue is, of course of

00:14:38.010 --> 00:14:39.979
concern because
patient safety is is

00:14:40.079 --> 00:14:42.381
fundamental. We
collect all these these

00:14:42.481 --> 00:14:45.351
data and we look at
all the clinical data

00:14:45.451 --> 00:14:48.287
we have. Each and
every safety report is

00:14:48.387 --> 00:14:51.457
investigated. We feel
that we have a robust

00:14:51.557 --> 00:14:54.293
data set and we share
that with the

00:14:54.393 --> 00:14:57.129
authorities who do
investigate this.

00:14:57.229 --> 00:15:00.199
But we believe that
there is no concerns

00:15:00.299 --> 00:15:02.601
besides what is
already established in

00:15:02.701 --> 00:15:03.002
And while those effects
aren't widespread, they

00:15:03.102 --> 00:15:04.803
the label.

00:15:04.904 --> 00:15:06.605
could derail the
company's growth.

00:15:06.705 --> 00:15:09.441
You could go all the
way back to 2003, 2004

00:15:09.541 --> 00:15:13.245
with Vioxx, Celebrex
and Bextra, the Cox two

00:15:13.345 --> 00:15:15.381
inhibitors, where
those products were

00:15:15.481 --> 00:15:19.051
projected to be 15 to
$20 billion market, it

00:15:19.151 --> 00:15:23.022
actually ended up sort
of reversing and going

00:15:23.122 --> 00:15:25.591
back to, you know, a
$3 billion market.

00:15:25.691 --> 00:15:27.159
Do we think that's
going to happen here?

00:15:27.259 --> 00:15:28.427
Absolutely not.

00:15:28.527 --> 00:15:30.663
For Mary, so far, side
effects aren't a

00:15:30.763 --> 00:15:31.497
concern.

00:15:32.665 --> 00:15:33.899
A negative.

00:15:34.133 --> 00:15:35.200
Like whatever.

00:15:35.301 --> 00:15:37.002
If I'm still around in
20 years, I'll be

00:15:37.102 --> 00:15:37.903
thrilled.

00:15:38.837 --> 00:15:40.306
What is an issue?

00:15:40.406 --> 00:15:41.607
Price.

00:15:41.707 --> 00:15:45.311
Pens cost about $1000
to $1300 a month out of

00:15:45.411 --> 00:15:48.047
pocket and if used
correctly, should be

00:15:48.147 --> 00:15:49.748
taken indefinitely.

00:15:49.848 --> 00:15:52.751
As of 2023, Medicare
does not cover Wegovy

00:15:52.918 --> 00:15:55.487
and only some plans
fully cover Ozempic and

00:15:55.587 --> 00:15:57.723
Mounjaro for
diabetics; putting

00:15:57.823 --> 00:16:00.125
another barrier
between US users and

00:16:00.225 --> 00:16:01.226
the drugs.

00:16:01.393 --> 00:16:04.229
We have a situation
where there's a very

00:16:04.363 --> 00:16:06.432
steep demand and we
cannot meet that

00:16:06.532 --> 00:16:08.667
demand. And I can only
think about what it

00:16:08.767 --> 00:16:10.235
would mean if we start
giving it away.

00:16:10.336 --> 00:16:11.470
So we cannot do that.

00:16:11.570 --> 00:16:14.006
But that too could
change as society's

00:16:14.106 --> 00:16:16.241
understanding of
obesity evolves.

00:16:16.342 --> 00:16:18.644
The American Medical
Association officially

00:16:18.744 --> 00:16:21.580
recognized obesity as
a disease in 2013.

00:16:21.680 --> 00:16:23.816
American Medical
Association is changing

00:16:23.916 --> 00:16:26.318
this concept of BMI.

00:16:26.418 --> 00:16:30.022
They said that
insurances cannot deny

00:16:30.122 --> 00:16:32.992
weight loss medication
based purely on the

00:16:33.092 --> 00:16:35.928
BMI. Now, that is
huge, and that's going

00:16:36.028 --> 00:16:38.597
to open the door for
many other patients to

00:16:38.697 --> 00:16:40.399
have access to this
drug.

00:16:40.799 --> 00:16:43.068
The big question is
whether the American

00:16:43.168 --> 00:16:45.204
insurance system can
support coverage for

00:16:45.304 --> 00:16:47.072
millions of people
needing these

00:16:47.172 --> 00:16:47.806
treatments in the
future.

00:16:48.407 --> 00:16:50.976
These two drugs are
going to have multiple

00:16:51.076 --> 00:16:53.946
benefits for patients
in a variety of health

00:16:54.046 --> 00:16:56.949
areas. So if that's
the case, I think we

00:16:57.049 --> 00:17:00.019
have to consider can
insurance afford all of

00:17:00.119 --> 00:17:02.521
this? And if they
can't, what do they do

00:17:02.621 --> 00:17:03.389
about it?

00:17:03.622 --> 00:17:04.957
Analysts predict that
competition among

00:17:05.057 --> 00:17:06.458
pharmaceutical
companies, along with

00:17:06.558 --> 00:17:09.261
availability, will
eventually drive prices

00:17:09.361 --> 00:17:10.229
down.

00:17:10.329 --> 00:17:13.632
The obesity treatments
will be available

00:17:13.732 --> 00:17:16.301
ultimately, you know,
certainly a decade or

00:17:16.402 --> 00:17:18.637
more from now for
pennies on the dollar.

00:17:18.737 --> 00:17:21.006
And so treating
obesity may become

00:17:21.106 --> 00:17:22.174
dramatically easier.

00:17:22.274 --> 00:17:24.309
To get there. Novo
Nordisk will first have

00:17:24.410 --> 00:17:26.645
to tackle quality
control on September

00:17:26.745 --> 00:17:29.748
21st, 2023, Reuters
reported the FDA had

00:17:29.848 --> 00:17:31.884
found manufacturing
shortfalls in the

00:17:31.984 --> 00:17:33.419
company's North
Carolina production

00:17:33.519 --> 00:17:36.355
plant in July that
could date back to May.

00:17:36.455 --> 00:17:38.524
Stocks fell by 3%.

00:17:38.624 --> 00:17:41.360
In a statement to
CNBC, Novo Nordisk said

00:17:41.460 --> 00:17:43.762
the FDA does hundreds
of routine inspections

00:17:43.862 --> 00:17:44.296
with all
pharmaceutical

00:17:44.863 --> 00:17:45.898
companies every year.

00:17:45.998 --> 00:17:48.033
Novo Nordisk has
responded to the FDA

00:17:48.133 --> 00:17:50.335
observations and the
facility continues to

00:17:50.436 --> 00:17:52.271
run and produce for
the market.

00:17:52.371 --> 00:17:55.040
Even if Novo Nordisk
and its peers can

00:17:55.140 --> 00:17:56.942
achieve the lofty goal
of helping those

00:17:57.042 --> 00:17:59.511
suffering from
obesity, there are some

00:17:59.611 --> 00:18:00.746
apprehensions.

00:18:00.846 --> 00:18:04.450
If Eli Lilly and Novo
Nordisk can continue to

00:18:04.550 --> 00:18:07.786
deliver and meet the
demand, then it could

00:18:07.886 --> 00:18:10.022
really change the
world. There is another

00:18:10.122 --> 00:18:13.492
risk. It could be
something completely

00:18:13.592 --> 00:18:17.162
different than just a
drug, but something you

00:18:17.262 --> 00:18:19.398
could use as you use
makeup.

00:18:19.898 --> 00:18:22.901
Maybe people would
forget to do exercise

00:18:23.001 --> 00:18:25.704
and to to eat healthy
because we simply take

00:18:25.804 --> 00:18:27.840
a drug. We are only
scratching the surface.

00:18:27.940 --> 00:18:30.676
And that's a little
bit scary, in fact.

00:18:30.776 --> 00:18:32.444
Still, according to the
company's leader, the

00:18:32.544 --> 00:18:33.745
attempt is worth the
risk.

00:18:34.613 --> 00:18:37.583
I think nowadays we
mankind is not

00:18:37.683 --> 00:18:39.451
struggling because of
infections, but I think

00:18:39.551 --> 00:18:41.019
we are struggling
because of of how we

00:18:41.120 --> 00:18:45.224
live. And with aging
populations, we see

00:18:45.324 --> 00:18:47.993
less and less
productive workers

00:18:48.093 --> 00:18:50.729
living with more and
more chronic diseases

00:18:50.829 --> 00:18:52.164
like cardiometabolic
diseases.

00:18:53.065 --> 00:18:56.368
And if we can address
that in in safe,

00:18:56.468 --> 00:18:58.837
efficacious ways, I
think that's good for

00:18:58.937 --> 00:19:01.240
all of us. I think
medical history will

00:19:01.340 --> 00:19:03.342
look back at
semaglutide as as one

00:19:03.442 --> 00:19:05.344
of the major
breakthroughs, a

00:19:05.444 --> 00:19:08.013
molecule that kept
giving, so to say.